More Invex Therapeutics Ltd. news
Invex Therapeutics Ltd.ASX: IXC

Invex receives IND approval

Aug 18, 2022 at 11:46 PM EDT · Issued by Invex Therapeutics Ltd.

Filed with ASX · Aug 18, 2022 at 11:46 PM EDT

On 6ix: 6ix.com/news/invex-receives-ind-approval

Invex Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Invex Therapeutics Ltd. on 6ix

Story so far

  • HREC and TGA Approval to Commence Phase 3 in AustraliaJul 4, 2022
  • Invex Receives UK Approval to Commence Phase III TrialJun 29, 2022
  • Invex Granted Key European Patent for ExenatideAug 16, 2021

Earlier from Invex Therapeutics

  • Quarterly Activities/Appendix 4C Cash Flow ReportJul 5, 2022
  • HREC and TGA Approval to Commence Phase 3 in AustraliaJul 3, 2022
  • Invex Receives UK Approval to Commence Phase III TrialJun 28, 2022
  • Half Yearly Report and AccountsFeb 22, 2022
  • New Executive Director and Chairman AgreementsJan 30, 2022

Later from Invex Therapeutics

  • 4E and Annual Report to shareholdersAug 18, 2022
  • Second HREC Approval for IIH EVOLVE Phase III Clinical TrialSep 29, 2022
  • First Australian Site Activated in IIH EVOLVE Phase 3Oct 23, 2022
  • First UK Clinical Site Activated in IIH EVOLVE Phase 3 TrialOct 23, 2022
  • Invex Receives $0.46 Million R&D Tax RebateOct 31, 2022
All Invex Therapeutics news releases↗

Follow Invex Therapeutics into a list and get an email when it puts out news.

Follow Invex Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer